Myasthenic Crisis — Respiratory and Immunotherapy

Key Points

• Myasthenic crisis is defined by severe weakness causing or threatening respiratory failure, not by a specific oxygen saturation or spirometry value.
• Pulse oximetry can remain normal despite dangerous neuromuscular ventilatory weakness.
• Serial forced vital capacity, inspiratory strength, cough, bulbar function, and clinical trajectory are more useful than one isolated measurement.
• Intubate before exhaustion or aspiration when respiratory or bulbar weakness is progressing.
• Plasma exchange and IVIG are the principal rapid immunomodulatory therapies for crisis.
• Look actively for infection, medication exposure, surgery, pregnancy-related changes, and treatment interruption as precipitants.
• Pyridostigmine is often held after intubation because it can increase secretions.
• Extubation requires recovery of cough and bulbar function as well as adequate ventilatory mechanics.

Algorithm

1. Assess airway protection, speech, swallowing, cough, secretion burden, respiratory rate, work of breathing, neck flexion, and generalized weakness.
2. Obtain serial forced vital capacity and inspiratory force when feasible, but interpret them alongside the clinical trajectory.
3. Place the patient in ICU-level monitoring and identify infection, medication triggers, or other precipitants.
4. Use noninvasive ventilation only in carefully selected patients with preserved airway protection and close monitoring.
5. Proceed to early controlled intubation for worsening respiratory mechanics, hypercapnia, severe bulbar dysfunction, weak cough, secretion failure, or rapid clinical decline.
6. Begin plasma exchange or IVIG promptly in consultation with neurology.
7. Treat infection and remove drugs that worsen neuromuscular transmission.
8. Coordinate corticosteroid and long-term immunotherapy adjustments with neurology.
9. If intubated, manage pyridostigmine according to secretion burden and neurology guidance.
10. Assess cough, secretion handling, bulbar strength, and respiratory mechanics before extubation.

Clinical Synopsis & Reasoning

Myasthenic crisis is a life-threatening exacerbation of myasthenia gravis in which respiratory muscle or bulbar weakness is severe enough to require or threaten ventilatory support. The central danger is that oxygen saturation can remain normal until late because the primary problem is ventilatory muscle failure rather than intrinsic lung disease. A patient can therefore appear deceptively stable while tidal volume and cough strength deteriorate. Serial bedside assessment of speech, counting ability, neck flexion, secretion handling, cough, respiratory rate, forced vital capacity, and inspiratory force is more informative than pulse oximetry alone.

Symptoms can include rapidly worsening ptosis, diplopia, dysarthria, dysphagia, nasal speech, weak cough, inability to hold the head up, orthopnea, accessory muscle use, paradoxical breathing, and generalized fatigable weakness. Bulbar weakness raises aspiration risk even before ventilatory measurements become severely abnormal. Precipitants include respiratory or urinary infection, surgery, pregnancy or postpartum physiology, medication changes, inadequate immunosuppression, and drugs that impair neuromuscular transmission. Common medication concerns include aminoglycosides, fluoroquinolones, macrolides, magnesium, selected antiarrhythmics, and neuromuscular blocking agents.

Differentiate myasthenic crisis from cholinergic toxicity, botulism, Guillain-Barré syndrome, brainstem stroke, electrolyte disorders, and other causes of neuromuscular respiratory failure. Cholinergic crisis from excessive acetylcholinesterase inhibition is now uncommon and is suggested by muscarinic findings such as diarrhea, salivation, miosis, and bradycardia in addition to weakness. Infection can both trigger crisis and complicate mechanical ventilation, so targeted infectious evaluation is important without delaying respiratory support.

Treatment Strategy & Disposition

Admit suspected myasthenic crisis to an ICU or equivalent setting with frequent respiratory assessment. Provide oxygen when hypoxemic, but do not use oxygen saturation as reassurance that ventilation is adequate. Noninvasive ventilation can be considered in carefully selected cooperative patients with preserved bulbar function and manageable secretions, but it should not delay intubation when respiratory mechanics are worsening, carbon dioxide is rising, the patient cannot protect the airway, or secretions cannot be cleared.

Intubate electively before respiratory arrest when clinical trajectory indicates impending failure. Commonly cited concerning measurements include forced vital capacity around 15 to 20 mL/kg and markedly reduced negative inspiratory force, but no single threshold should override bedside findings. Bulbar failure, weak cough, rapid decline, tachypnea, hypercapnia, and inability to manage secretions are major indications for airway control. Use sedatives and neuromuscular blockers cautiously because patients with MG have altered responses to paralytics.

Rapid disease-directed therapy is plasma exchange or intravenous immune globulin. Both are established treatments for severe exacerbation and crisis; plasma exchange may act somewhat faster in some settings, while IVIG can be easier to administer. Choice depends on hemodynamic stability, vascular access, renal function, thrombotic risk, local expertise, and prior response. Corticosteroids and longer-term immunotherapy should be coordinated with neurology because initiating or escalating steroids can transiently worsen weakness before improvement.

Pyridostigmine is often held or reduced after intubation because excess airway secretions can complicate ventilation and aspiration prevention; it is restarted as strength improves and extubation approaches under neurology guidance. Treat the precipitating infection or other trigger and avoid medications that worsen neuromuscular transmission whenever alternatives exist. Extubation should wait until respiratory strength, cough, secretion control, and bulbar function have recovered, not simply until a numerical vital-capacity threshold is met.

Epidemiology / Risk Factors

• Myasthenic crisis occurs in a minority of patients with myasthenia gravis but remains a major cause of ICU admission in the disease.
• Infection is one of the most common precipitants.
• Bulbar-predominant disease and prior crisis increase concern for respiratory decompensation.
• Pregnancy and the postpartum period can alter MG activity and medication requirements.
• Modern ventilatory and immunomodulatory care has markedly improved survival compared with the pre-ICU era.

Investigations

Intubation Thresholds (Typical)

Pharmacology

Prognosis / Complications

• Most patients recover from crisis with ventilatory support and rapid immunotherapy.
• Duration of ventilation varies with precipitant, baseline disease burden, bulbar involvement, and treatment response.
• Complications such as ventilator-associated pneumonia, aspiration, thrombosis, and prolonged weakness can lengthen recovery.
• Recurrent crisis risk is reduced by addressing triggers and optimizing chronic MG therapy.
• Long-term neurologic outcome is often good when prolonged hypoxic injury and major ICU complications are avoided.

Patient Education / Counseling

• Teach patients to seek urgent care for rapidly worsening swallowing, speech, cough, orthopnea, or breathing weakness.
• Review medications that can worsen myasthenia and encourage patients to inform every clinician of the diagnosis.
• Explain that normal oxygen saturation does not necessarily mean breathing muscles are strong enough.
• After recovery, arrange neurology follow-up to optimize maintenance immunotherapy and reduce recurrence risk.
• Encourage vaccination and early evaluation of infections when appropriate because infection commonly triggers crisis.
• Discuss pregnancy planning and medication safety with neurology and obstetrics for patients who may become pregnant.

Notes

Respiratory decision-making in MG should be intentionally clinical. Fixed spirometric cutoffs are useful warning points but do not replace assessment of bulbar weakness, cough, secretion control, work of breathing, and trend. Patients can deteriorate while maintaining normal oxygen saturation.

The Myasthenia Gravis Foundation of America emphasizes the value of forced vital capacity and bedside respiratory observation and notes that IVIG or plasma exchange are key rescue therapies. Neurology and critical care involvement should occur early rather than after respiratory arrest.

References

1. Myasthenia Gravis Foundation of America: Emergency Management for First Responders — Link
2. Myasthenia Gravis Foundation of America: Treatment Resources — Link